Chugai Receives MHLW’s Approval for the Expanded Use of FoundationOne CDx as a Companion Diagnostic of Rozlytrek (entrectinib)

 Chugai Receives MHLW’s Approval for the Expanded Use of FoundationOne CDx as a Companion Diagnostic of Rozlytrek (entrectinib)

Chugai Receives MHLW’s Approval for the Expanded Use of FoundationOne CDx as a Companion Diagnostic of Rozlytrek (entrectinib)

Shots:

  • The MHLW has approved the expanded use of FoundationOne CDx for Rozlytrek to treat ROS1 fusion-positive, LA/ m-NSCLC, allowing the physician to identify NSCLC patients who could benefit from Rozlytrek by detecting ROS1 fusion genes
  • On Mar 15, 2019, Chugai has filed an application for the additional indication of Rozlytrek. Chugai will further expand the CDx functions of FoundationOne CDx for its in-house therapies and in collaboration with other biopharma partners
  • Rozlytrek is an oral tyrosine kinase inhibitor targeting ROS1 and TRK kinase activity, thus inhibiting the proliferation of cancer cells with ROS1 or NTRK gene fusions. FoundationOne CDx is a sequencing-based in vitro diagnostic device that detects mutations in 324 genes, select gene rearrangements and genomic signatures including MSI & TMB

Click here to­ read full press release/ article | Ref: Chugai Pharmaceutical  | Image:  Chugai Pharmaceutical

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post